在与艾滋病毒感染者发生性关系的男性中进行门癌查:益处,危害和成本效益分析
Ashish A Deshmukh1, Haluk Damgacioglu1, Keith Sigel2
1Department of Public Health Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina (A.A.D., H.D., K.Sonawane).
Annals of internal medicine
|June 16, 2025
概括
门癌症查对35岁及以上感染艾滋病毒的与男性发生性关系的男性 (MSM) 是具有成本效益的. 优先考虑的策略优化了对这个高风险群体的查使用.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
背景情况:
- 在ANCHOR试验之后,建议对高风险个人进行门癌症查,特别是与艾滋病毒感染的男性发生性关系的男性 (MSM).
- 美国卫生与人类服务部支持对这一群体进行门癌症查.
研究的目的:
- 评估各种癌查策略的成本效益和平衡好处与危害.
- 确定艾滋病毒感染的MSM的最佳查方法.
主要方法:
- 采用微模拟模型,利用ANCHOR试验和已发表文献的数据.
- 该研究分析了不同的查干预措施,包括细胞学,人类乳头瘤病毒 (HPV) 测试 (hrHPV,HPV16/18,HPV16),联合测试和分拣选项.
- 评估了查开始的年龄 (≥35,≥40,≥45) 和间隔 (每年至每四年).
主要成果:
- 35岁或以上的细胞学查启动比以后的启动更具成本效益.
- 一些策略,包括HPV16/18测试和hrHPV测试与分拣,证明了成本效益.
- 在危害与益处分析中,对高分辨率异常镜 (HRA) 的分离选择被证明是最有效的.
结论:
- 门癌症查对35岁及以上的感染艾滋病毒的MSM来说是一个具有成本效益的干预措施.
- 对选策略的基于价值的优先考虑对于优化资源配置和最大化收益至关重要.
- 这些发现是针对研究人口的具体发现,不能将其推广到其他高风险群体.
相关概念视频
Sexually Transmitted Infections
425
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
425
Disorders of the Male Reproductive System
617
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
617
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Comparing the Survival Analysis of Two or More Groups
303
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
303
Hazard Ratio
263
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
263


